光大证券：君实生物特瑞普利单抗放量，业绩持续减亏
财中社11月18日电光大证券发布研报称，君实生物（688180）近期发布2024年三季报，前三季度实现收入12.71亿元，同比增长28.9%；归母净利润净亏损9.27亿元，同比减亏4.80亿元；扣非归母净利润净亏损9.40亿元，同比减亏4.20亿元。其中三季度单季度收入4.85亿元，同比增长53.2%；归母净利润净亏损2.82亿元，同比减亏1.28亿元；扣非归母净利润净亏损3.13亿元，同比减亏0.75亿元。
特瑞普利单抗持续放量，提质增效效果明显。公司核心产品特瑞普利单抗24年前三季度实现销售收入10.68亿元，同比增长约60%，单三季度销售收入约3.97亿元，同比增长约79%。
考虑到特瑞普利单抗销售爬坡、提质增效聚焦核心研发项目持续推进，上调公司2024~2025年归母净利润预测为-9.2、-3.8亿元（前次为-13.8、-7.7亿元），新增2026年归母净利润预测为3.4亿元，公司是国内创新药第一梯队企业，国际化进程加快，维持A股/H股“买入”评级。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10